CXCL12 and age-related macular degeneration: As shown in figure 4C, 25 ng/ml AMD 3100 treatment significantly prevented cell migration towards SDF-1α in an in vitro system, and the migrated cells number of AMD-treated group decreased by about 40% compared with the control.